Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medco Rethinks Part D: Bailing Out or Mailing it In?

This article was originally published in RPM Report

Executive Summary

Medco shed over 100,000 Part D members in 2007 and the company couldn't be happier. Medco says it has no interest in serving the poorest Medicare beneficiaries, because they do not use mail order and can't be given viable economic incentives to do so. If other plans start to think like Medco, Part D advocates may have reasons to worry.

You may also be interested in...

Medicare Rx at a Turning Point: Big Plans Stumble as Part D Enters a Pivotal Year

United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.

The End of the PDP? What MemberHealth Means for Medicare Part D

The merger of MemberHealth into Universal American is the biggest Part D deal so far-and the first of what is sure to be many ripple effects from the CVS/Caremark agreement. Universal's model relies on cross-selling in Medicare Advantage. The era of the stand-alone drug plan may be ending.

Making Part D Stick: Lessons From the First Year of Medicare Rx

Medicare beneficiaries stuck with their Part D plans heading into 2007. That gives insurers more leverage in price negotiations with big pharma. It also means Part D may be more likely to stick around despite critics in the Democratic Congress.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts